Syndax (SNDX) | Financial Analysis & Statements
Syndax Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
68.7M
Gross Profit
66.0M
96.06%
Operating Income
-62.5M
-91.01%
Net Income
-68.0M
-98.96%
EPS (Diluted)
$-0.78
Balance Sheet Metrics
Total Assets
529.7M
Total Liabilities
465.1M
Shareholders Equity
64.6M
Debt to Equity
7.20
Cash Flow Metrics
Operating Cash Flow
-123.2M
Free Cash Flow
-69.5M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Syndax Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 172.4M | 23.7M | 0 | 0 | 139.7M |
| Cost of Goods Sold | 7.0M | 826.0K | - | - | - |
| Gross Profit | 165.4M | 22.9M | - | - | - |
| Gross Margin % | 96.0% | 96.5% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 258.8M | 241.6M | 163.0M | 118.5M | 88.2M |
| Selling, General & Administrative | 179.7M | 120.9M | 66.9M | 33.3M | 25.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 438.5M | 362.5M | 230.0M | 151.8M | 113.5M |
| Operating Income | -273.1M | -339.7M | -230.0M | -151.8M | 26.2M |
| Operating Margin % | -158.4% | -1,434.4% | 0.0% | 0.0% | 18.8% |
| Non-Operating Items | |||||
| Interest Income | 22.7M | 26.1M | 21.2M | 5.9M | 403.0K |
| Interest Expense | 33.8M | 4.9M | 208.0K | 3.1M | 1.9M |
| Other Non-Operating Income | -1.3M | -247.0K | -361.0K | -316.0K | 202.0K |
| Pre-tax Income | -285.4M | -318.8M | -209.4M | -149.3M | 24.9M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -285.4M | -318.8M | -209.4M | -149.3M | 24.9M |
| Net Margin % | -165.6% | -1,346.1% | 0.0% | 0.0% | 17.8% |
| Key Metrics | |||||
| EBITDA | -251.6M | -313.8M | -209.1M | -146.2M | 26.9M |
| EPS (Basic) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.48 |
| EPS (Diluted) | $-3.29 | $-3.72 | $-2.98 | $-2.46 | $0.48 |
| Basic Shares Outstanding | 86625610 | 85622065 | 70370519 | 60760906 | 52064809 |
| Diluted Shares Outstanding | 86625610 | 85622065 | 70370519 | 60760906 | 52064809 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Syndax Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 134.9M | 154.1M | 295.4M | 74.4M | 222.0M |
| Short-term Investments | 278.8M | 428.8M | 282.2M | 410.0M | 224.9M |
| Accounts Receivable | 38.0M | 7.6M | 0 | 3.5M | 0 |
| Inventory | 32.8M | 366.0K | - | - | - |
| Other Current Assets | 1.2M | 612.0K | 63.0K | 117.0K | 150.0K |
| Total Current Assets | 528.1M | 603.1M | 580.9M | 489.8M | 448.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.6M | 2.1M | 1.6M | 1.1M | 1.4M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 102.0K | 217.0K | 680.0K | 922.0K | - |
| Total Non-Current Assets | 1.6M | 121.8M | 32.0M | 7.4M | 1.3M |
| Total Assets | 529.7M | 724.8M | 612.9M | 497.2M | 449.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 16.6M | 11.6M | 17.2M | 4.4M | 5.7M |
| Short-term Debt | 472.0K | 12.6M | 1.0M | 439.0K | 362.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 10.5M | 1.3M | 888.0K | 604.0K | 1.9M |
| Total Current Liabilities | 120.1M | 103.5M | 58.1M | 29.1M | 20.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 345.0M | 333.1M | 588.0K | 722.0K | 20.6M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 345.0M | 333.1M | 588.0K | 722.0K | 20.6M |
| Total Liabilities | 465.1M | 436.7M | 58.7M | 29.8M | 41.3M |
| Equity | |||||
| Common Stock | 9.0K | 9.0K | 8.0K | 7.0K | 6.0K |
| Retained Earnings | -1.5B | -1.2B | -902.4M | -693.0M | -543.7M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 64.6M | 288.1M | 554.2M | 467.4M | 408.4M |
| Key Metrics | |||||
| Total Debt | 345.4M | 345.7M | 1.6M | 1.2M | 21.0M |
| Working Capital | 408.0M | 499.5M | 522.8M | 460.7M | 427.7M |
Balance Sheet Composition
Syndax Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -285.4M | -318.8M | -209.4M | -149.3M | 24.9M |
| Depreciation & Amortization | 6.0K | 8.0K | 12.0K | 33.0K | 43.0K |
| Stock-Based Compensation | 47.5M | 43.0M | 31.0M | 16.0M | 13.3M |
| Working Capital Changes | -106.9M | 2.5M | 16.3M | -8.3M | -11.0M |
| Operating Cash Flow | -343.5M | -272.2M | -161.3M | -140.0M | 27.5M |
| Investing Activities | |||||
| Capital Expenditures | -187.0K | 0 | 0 | 225.0K | -129.0K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -195.8M | -557.1M | -354.6M | -495.3M | -294.7M |
| Investment Sales | 486.0M | 337.3M | 472.2M | 308.9M | 254.0M |
| Investing Cash Flow | 290.0M | -219.8M | 117.6M | -186.2M | -40.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 0 |
| Debt Repayment | - | 0 | 0 | -21.0M | 0 |
| Financing Cash Flow | 0 | 343.7M | 258.1M | 160.4M | 86.9M |
| Free Cash Flow | -323.2M | -274.9M | -160.6M | -133.7M | 29.0M |
| Net Change in Cash | -53.5M | -148.3M | 214.4M | -165.8M | 73.5M |
Cash Flow Trend
Syndax Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-6.50
Forward P/E
-42.17
Price to Book
28.94
Price to Sales
10.95
PEG Ratio
0.22
Profitability Ratios
Profit Margin
-165.60%
Operating Margin
-91.59%
Return on Equity
-161.83%
Return on Assets
-27.25%
Financial Health
Current Ratio
4.40
Debt to Equity
534.48
Beta
0.41
Per Share Data
EPS (TTM)
$-3.29
Book Value per Share
$0.74
Revenue per Share
$1.99
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SNDX | 1.9B | -6.50 | 28.94 | -161.83% | -165.60% | 534.48 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Taysha Gene | 1.8B | 2.53 | 7.39 | -68.45% | 0.00% | 28.41 |
Financial data is updated regularly. All figures are in the company's reporting currency.






